What is AVBP's market cap?

$665.16M, based on the Nov 4 close of $13.49.

Does ArriVent BioPharma pay a dividend?

No regular cash dividend has been paid in the last year.

How much of AVBP is sold short?

6.8M shares, 20.3% of float, as of Oct 15, 2026.

What sector is AVBP in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · AVBPHealthcarePharmaceuticals

ArriVent BioPharma, Inc. Common Stock (AVBP)

$13.49+3.61%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$12.87▼ 26.88% in range

Nov 3, 2025Low $12.87 · High $34.74Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

ArriVent BioPharma closed at $13.49 on Nov 4, up 3.61%, 61.2% below its 52-week closing high. Volume of 1.9M shares was 1.05× its 20-day average (close to normal).

Split-adjusted performance: -10.6% over one month, -54.5% over six months, -23.4% over one year.

Short interest was 6.8M shares at the Oct 15 settlement, down 19.5% from the prior report (20.3% of float, 2.2 days to cover).

Market cap$665.2M49.3M shares

Revenue · quarter$0.00—

Diluted EPS$-1.05—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range13.02 – 34.74−61.2% from high

Volume1.9M1.05× 20-day avg

Volatility · 60d154.6%Annualised

Short % of float20.3%2.2 days to cover

Net cash$373.1MCash $373.1M

Next earnings—Not scheduled

Split-adjusted performance

1W −14.2%1M −10.6%3M −56.5%6M −54.5%YTD −33.0%1Y −23.4%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum22

Revenue growth—

Net margin—

Value (low P/E)—

Size65

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short6.8M−19.5% vs prior

Days to cover2.2Settled Oct 15

% of float20.3%

Short vol. 10d42.9%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
AVBPArriVent BioPharma	$13.49	+3.61%	−54.5%	—	—	—	$665.2M
DSGNDesign Therapeutics	$10.63	+2.80%	−26.9%	—	—	—	$665.2M	Compare
ZVRAZevra Therapeutics	$11.17	+8.87%	−0.7%	+44.9%	48.8%	8.6	$663.3M	Compare
IMMXImmix Biopharma	$7.97	+3.37%	−22.8%	—	—	—	$660.7M	Compare
OLMAOlema Pharmaceuticals	$7.54	+2.58%	−50.4%	—	—	—	$659.7M	Compare
LXRXLexicon Pharmaceuticals	$1.48	+1.37%	−7.5%	−97.6%	−4591.8%	—	$658.5M	Compare
KURAKura Oncology	$7.61	−22.98%	−20.4%	+36.5%	−327.3%	—	$677.0M	Compare
OBXObsidian Therapeutics	$10.99	−16.93%	—	—	—	—	$678.9M	Compare
GERNGeron	$1.08	+16.13%	−31.6%	+17.2%	−29.0%	—	$693.9M	Compare

News about ArriVent BioPharma

All news →

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026GlobeNewswire Inc. · Oct 25, 2026▲ Positive ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026GlobeNewswire Inc. · Oct 23, 2026▲ Positive ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial CancersGlobeNewswire Inc. · May 7, 2026▲ Positive ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual MeetingGlobeNewswire Inc. · Mar 17, 2026▲ Positive

Quick answers

What does ArriVent BioPharma do?: ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
What is AVBP's market cap?: $665.16M, based on the Nov 4 close of $13.49.
Does ArriVent BioPharma pay a dividend?: No regular cash dividend has been paid in the last year.
How much of AVBP is sold short?: 6.8M shares, 20.3% of float, as of Oct 15, 2026.
What sector is AVBP in?: Healthcare, in the Pharmaceuticals industry.

About ArriVent BioPharma

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

HQ: Newtown Square, PA77 employeesListed Jan 26, 2024arrivent.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology